rs4349859 — HLA-B HLA-B27 proxy

Intronic tag SNP located 41 kb centromeric of HLA-B and 5.4 kb telomeric of MICA; the A allele tags HLA-B*27:05 and related European HLA-B27 subtypes with 98% sensitivity and 99% specificity, serving as a genetic proxy for HLA-B27 status and enabling contextualization of ERAP1 × HLA-B27 epistasis in ankylosing spondylitis risk

See your personal result for HLA-B

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

HLA-B27 Status — The Dominant Genetic Risk Factor for Ankylosing Spondylitis

HLA-B2711 HLA-B27
Human Leukocyte Antigen B*27 — a class I MHC molecule encoded in the highly polymorphic HLA region of chromosome 6, present in approximately 8% of Europeans and 60–90% of ankylosing spondylitis patients worldwide represents the single strongest genetic association with any common disease known to medicine — individuals carrying this allele face a roughly 60-fold increased risk for ankylosing spondylitis (AS) compared to non-carriers. Direct HLA typing is complex and expensive, but rs4349859 — a common intronic SNP located 41 kb centromeric of the HLA-B gene and 5.4 kb telomeric of MICA — serves as a highly accurate genetic proxy for European HLA-B27 subtypes, making it possible to infer HLA-B27 status directly from standard genotyping arrays.

The A allele of rs4349859 arose on a chromosome bearing HLA-B27 in an ancestor shared by nearly all European and some Asian HLA-B27 carriers. This ancient founder event means the A allele travels with HLA-B27 in strong linkage disequilibrium22 linkage disequilibrium
a statistical association between alleles at nearby loci that persists across generations because recombination has not yet broken apart the ancestral haplotype, allowing the SNP to stand in for direct HLA-B27 typing in research and clinical screening applications.

The Mechanism

rs4349859 is an intronic variant in MICA-AS1 (MICA antisense RNA 1), a non-coding RNA gene located between HLA-B and MICA in the MHC class I region. The SNP itself has no known functional consequence — it does not change any protein or alter gene expression. Its clinical relevance derives entirely from the haplotype it marks: the A allele at rs4349859 is a reliable indicator that the individual carries an HLA-B27 allele33 HLA-B27 allele
most commonly HLA-B*27:05 in Europeans, the primary AS-associated subtype; also tags B*2702, B*2708, and B*2709 on the same chromosome.

HLA-B27 itself causes disease through several proposed mechanisms. The arthritogenic peptide hypothesis holds that HLA-B27 presents self-peptides (or microbial peptides with structural similarity to self) to CD8+ T cells, triggering an autoimmune cascade directed at joint tissues. Supporting this model, variants in ERAP1 — the enzyme that trims peptides before they are loaded onto HLA-B27 — affect AS risk exclusively in HLA-B27-positive individuals, directly implicating the peptide-HLA-B27 interaction in disease pathogenesis. A complementary hypothesis involves the spontaneous misfolding of HLA-B27 heavy chains into homodimers, which activate NK cells and innate lymphocytes independently of peptide presentation.

The Evidence

rs4349859 as HLA-B27 proxy. In the landmark epistasis study by Evans et al.44 Evans et al.
Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Nature Genetics, 2011, rs4349859 was used as the HLA-B27 proxy across a discovery cohort of 1,787 British and Australian cases plus 4,800 controls and a replication cohort of 2,111 cases and 4,483 controls. The SNP achieved 98.0% sensitivity and 99.0% specificity for HLA-B27 in the European ancestry subset (538 cases and 741 controls with known HLA-B27 status). The dominant model (A allele present = HLA-B27 positive) was used throughout, with the study confirming that ERAP1 variants have no detectable effect on AS risk in rs4349859 GG individuals (presumed HLA-B27-negative), but powerfully modify risk in A-allele carriers.

Population prevalence. A comprehensive New Zealand population study of 1,220 Caucasian controls found rs4349859 genotype frequencies of GG: 90.7%, AG: 8.8%, AA: 0.4%, corresponding to an A-allele frequency of ~4.7%55 corresponding to an A-allele frequency of ~4.7%, consistent with the approximately 8–9% HLA-B27 prevalence in Northern European populations (heterozygotes carry one A allele; both A alleles in homozygotes are rarer). Concordance with direct serological HLA-B27 typing was 98.7–100% in European-ancestry individuals. The SNP tags all major European AS-associated subtypes (B*2702, B*2705, B*2708) but does not tag African (B*2703) or most Asian subtypes (B*2704, B*2706, B*2707), limiting its utility to European-ancestry individuals.

HLA-B27 and AS risk. The overall odds ratio for AS given HLA-B27 positivity is approximately 60, the strongest common-variant disease association documented in human genetics. Despite this extraordinary OR, only 1–2% of HLA-B27-positive individuals develop AS in their lifetime66 Despite this extraordinary OR, only 1–2% of HLA-B27-positive individuals develop AS in their lifetime
population attributable risk is nonetheless substantial because B27 prevalence is 8% in Europeans and 60-90% of AS cases carry B27. Risk rises to approximately 20% if a first-degree relative has AS. HLA-B27 accounts for approximately 25% of AS heritability, with 116 additional genetic loci contributing ~30% combined.

Practical Implications

Knowing your rs4349859 genotype provides a genetic proxy for HLA-B27 status without the need for traditional HLA typing. For GG individuals (no A allele), the probability of carrying HLA-B27 is below 2%; residual risk comes from rare B27-positive individuals whose HLA-B27 subtype is not tagged by this SNP. For AG individuals (one A allele), HLA-B27 positivity is overwhelmingly likely — approximately 90% of A-allele carriers in European populations are HLA-B27 positive. For AA individuals (two A alleles), HLA-B27 positivity is essentially certain, and these individuals likely carry two HLA-B27 alleles.

The clinical significance of HLA-B27 positivity depends heavily on context. In isolation, carrying HLA-B27 (A allele at rs4349859) means a modestly elevated lifetime risk of AS (~1–2% absolute) that rises substantially with additional genetic risk (ERAP1 variants) or family history. The most important implication is that inflammatory back pain symptoms in an HLA-B27-positive individual should be evaluated rapidly for axial spondyloarthritis, since early treatment with NSAIDs has disease-modifying effects on radiographic progression.

Interactions

rs4349859 × ERAP1 variants (rs26653, rs30187, rs10050860): Epistasis in ankylosing spondylitis. This is the defining interaction for the entire ERAP1 locus. Evans et al. 2011 demonstrated unequivocally that all ERAP1 AS associations are conditional on HLA-B27 status77 Evans et al. 2011 demonstrated unequivocally that all ERAP1 AS associations are conditional on HLA-B27 status
ERAP1 SNPs show zero association with AS in HLA-B27-negative individuals (GG at rs4349859), while in HLA-B27-positive individuals (AG or AA at rs4349859), ERAP1 risk alleles confer 3–4-fold differences in AS risk. The combined interaction p-value was 7.3 × 10⁻⁶. This epistasis is mechanistically coherent: ERAP1 trims peptides that are subsequently loaded onto HLA-B27; HLA-B27 status determines whether the trimmed peptide repertoire reaches a disease-triggering threshold.

rs4349859 × rs12191877 (HLA-C*06:02 proxy): Co-occurring immune susceptibility. HLA-C*06:02 is the primary genetic risk factor for psoriasis. Individuals carrying both HLA-B27 (rs4349859 A allele) and HLA-C*06:02 (rs12191877 A allele) are at risk for both AS and psoriasis and face elevated risk for psoriatic arthritis, a spondyloarthritis subtype overlapping both conditions. ERAP1 variants interact with both HLA alleles, albeit through partially distinct mechanisms and peptide repertoires.

Genotype Interpretations

What each possible genotype means for this variant.

GG HLA-B27 Negative Normal

No HLA-B27 tag allele detected — very low genetic susceptibility to HLA-B27-associated spondyloarthritis

You carry two copies of the G allele at rs4349859, indicating the absence of the HLA-B27 tagging allele. In European populations this is the most common genotype (~90% of people). Individuals with GG genotype have less than 2% probability of carrying HLA-B27, making this genotype strongly associated with HLA-B27 negative status. The major genetic risk factor for ankylosing spondylitis, psoriatic arthritis, and reactive arthritis is absent, resulting in substantially lower baseline susceptibility to these conditions compared to A-allele carriers. Note: a small number of B27-positive individuals carry rare HLA-B27 subtypes (particularly African B*2703 or Asian B*2704, B*2706, B*2707) that are not tagged by this SNP; in individuals of non-European ancestry, rs4349859 GG does not fully rule out HLA-B27 carrier status.

AG HLA-B27 Positive High Risk

One HLA-B27 tag allele detected — you are very likely HLA-B27 positive, with substantially elevated ankylosing spondylitis susceptibility

HLA-B27 is a class I MHC molecule that presents peptide fragments from inside your cells to CD8+ T cells. The reason HLA-B27 causes disease is not fully understood, but two mechanisms have strong support. First, the arthritogenic peptide hypothesis: HLA-B27 may preferentially present certain microbial or self-derived peptides that trigger an autoimmune cascade directed at the sacroiliac joints and spine. Second, the misfolding hypothesis: HLA-B27 heavy chains tend to misfold in the endoplasmic reticulum and can form homodimers on the cell surface that activate NK cells and innate lymphocytes, generating inflammatory cytokines independently of peptide presentation.

The interplay with ERAP1 variants is the strongest mechanistic evidence for the arthritogenic peptide model. ERAP1 trims peptides to the right length for HLA binding; altered trimming changes the peptide repertoire that HLA-B27 presents; this shift toward aberrant peptides (or away from tolerogenic ones) appears to drive the downstream inflammatory response. This is why ERAP1 variants increase AS risk only in HLA-B27-positive individuals — without HLA-B27, the trimmed peptide repertoire does not reach the disease-triggering threshold.

Early symptoms of AS are often missed: the back pain is inflammatory (worse at night and in the morning, improves with movement) and typically begins before age 45. The average diagnostic delay in AS is 7–10 years from symptom onset, during which time irreversible joint fusion can begin. Knowing your HLA-B27 status enables much earlier diagnostic consideration when inflammatory symptoms arise.

AA HLA-B27 Homozygous High Risk

Two copies of the HLA-B27 tag allele — you are almost certainly carrying HLA-B27 on both chromosomes, conferring the highest genetic susceptibility to ankylosing spondylitis

HLA-B27 homozygosity is rare and the immunological consequences are not fully distinct from heterozygosity in most studies — likely because a single copy of HLA-B27 is sufficient to present arthritogenic peptides or generate misfolded heavy chain homodimers at pathogenic levels. Some studies suggest that homozygous AS patients may have earlier onset or more severe disease, though data are limited by the rarity of this genotype. In practical terms, the most important aspect of homozygosity is certainty: you almost certainly carry HLA-B27, and your ERAP1 variants should be interpreted in that full context. The ERAP1 × HLA-B27 epistasis documented by Evans et al. (combined interaction p=7.3×10⁻⁶) applies with full force to your genotype — any ERAP1 risk alleles you carry are fully operative as AS risk modifiers.